REGENERON PHARMACEUTICALS, INC. Repayments of Short-term Debt
REGENERON PHARMACEUTICALS, INC. (REGN) reported Repayments of Short-term Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-06.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfShortTermDebt · last filed 2023-02-06
- REGENERON PHARMACEUTICALS, INC. repayments of short-term debt for the quarter ending 2021-12-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. repayments of short-term debt for the quarter ending 2020-12-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. repayments of short-term debt for the quarter ending 2019-12-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. repayments of short-term debt for fiscal 2022 was $0.00.
- REGENERON PHARMACEUTICALS, INC. repayments of short-term debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- REGENERON PHARMACEUTICALS, INC. repayments of short-term debt for fiscal 2020 was $1.50B.
- REGENERON PHARMACEUTICALS, INC. repayments of short-term debt for fiscal 2019 was $0.00.
| Period end | Repayments of Short-term Debt 3 month | Repayments of Short-term Debt 9 month | Repayments of Short-term Debt 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-06 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $0.00 10-K · filed 2023-02-06 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $1.50B 10-K · filed 2023-02-06 | |
| 2020-09-30 | $1.50B 10-Q · filed 2021-11-04 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $0.00 10-K · filed 2022-02-07 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |